FDA approves Baxalta’s treatment for common bleeding disorder Approvals, Biotech, Bleeding, Bleeding Disorders, Blood Clots, Blood Clots, FDA, FDA/Regulatory, gegetic, Genetic Engineering, Genetics, Health, Hemophilia, Hemophilia, Immune Systems, Joints, Muscles, Oncology, Orphan Diseases, Orphan Drugs, Proteins, Rare Diseases, Shares, Shares, Willebrand Disease The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand […] Read more December 8, 2015/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2015-12-08 15:49:102015-12-09 02:42:37FDA approves Baxalta's treatment for common bleeding disorder